Grants and Support

Anthony J. Aldave, MD

California Institute for Regenerative Medicine

Role:               Principal Investigator
Duration:         08/01/23-02/28/26
Description:     AAV gene therapy for treating congenital hereditary endothelial dystrophy associated with biallelic SLC4A11 mutations

Foundation for the National Institutes of Health
Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)

Role:               Principal Investigator
Duration:         05/28/23-05/27/28
Description:     Phase I/II Safety and Efficacy Study of AAV-SLC4A11 Vector to Treat Congenital Hereditary Endothelial Dystrophy (CHED)

Santen Pharmaceuticals

Role:               Site Principal Investigator
Duration:         02/02/23-02/01/25
Description:     A Phase 2a, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehicle in Subjects with Fuchs endothelial corneal dystrophy

Doug Chung, PhD

Eye Bank Association of America

Role:               Principal Investigator
Duration:         07/01/23-06/30/24
Description:     Characterizing the transcriptomic profiles of cultured ex vivo corneal endothelial cells treated with mitochondria-targeted antioxidants during cell expansion

Wenlin Zhang, MD, PhD

Foundation for the National Institutes of Health
Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)

Role:               Co-Principal Investigator
Duration:         05/28/23-05/27/28
Description:     Phase I/II Safety and Efficacy Study of AAV-SLC4A11 Vector to Treat Congenital Hereditary Endothelial Dystrophy (CHED)

California Institute for Regenerative Medicine

Role:               Co-Principal Investigator
Duration:         08/01/23-02/28/26
Description:     AAV gene therapy for treating congenital hereditary endothelial dystrophy associated with biallelic SLC4A11 mutations